
According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of $62.87 million. In Q4, Arrowhead Pharmaceuticals brought in $38.28 million in sales but lost $63.37 million in earnings.